報價延遲最少15分鐘:2026/02/10 07:41 EST
盤前時段
|
||||
|
3.63 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.68
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.45/0.32
|
|
企業價值
1.65B
|
| 資產負債 |
|
每股賬面淨值
2.65
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
796.97M
|
|
每股收益
2.45
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000employees and 18 production sites mainly in Europe and the United States. |
